When to Avoid Noom: Specific Patient Profiles That Should Look Elsewhere

What Noom Actually Is (and Is Not)

Noom positions itself as a "psychology-first" weight-loss program, but the label requires unpacking before any patient decides whether it fits their situation. The core product is a smartphone app that delivers daily cognitive-behavioral micro-lessons, a food-logging interface, and access to a human "Goal Specialist" coach whose credentials are proprietary to Noom rather than licensed by any state board.

The App Layer

The lessons draw loosely from CBT and acceptance-and-commitment frameworks. Peer-reviewed evidence for app-delivered CBT in weight management exists, but it is modest. A 2021 Wiley meta-analysis in Obesity Reviews covering 41 trials found that app-based behavioral interventions produced a mean weight loss of 2.6 kg over 12 weeks compared with 0.7 kg in control groups, a statistically significant but clinically small difference [1].

Noom Med: The GLP-1 Tier

Since 2023, Noom has offered "Noom Med," a telehealth layer that allows a prescribing clinician to write semaglutide (Ozempic/Wegovy), bupropion-naltrexone (Contrave), or other agents. The prescriber interaction is primarily asynchronous. Patients who need titration guidance, lab draws, or cardiology clearance will not receive that through the standard Noom Med flow without escalation.

What Independent Oversight Shows

The Better Business Bureau lists Noom Inc. With a B- rating and more than 1,400 closed complaints as of July 2025, the majority citing unexpected charges, difficult cancellation, and auto-renewal billing that continued after users believed they had cancelled [2]. The FTC has separately published guidance warning consumers about subscription traps in the digital health space [3]. Neither the BBB nor the FTC rating constitutes a regulatory action, but the volume of billing complaints is a data point any prospective patient should weigh.

Patient Profile 1: Active or Recovering Eating Disorders

This is the clearest contraindication. Patients with a current or historical diagnosis of anorexia nervosa, bulimia nervosa, binge-eating disorder, or ARFID should not use Noom's standard product without explicit clearance from a treating eating-disorder specialist.

Why Calorie Color-Coding Can Cause Harm

Noom's food-logging system assigns foods a red, yellow, or green designation based on calorie density. For a patient in recovery from restrictive eating, this framework may reinforce food-morality cognitions that treatment teams work hard to dismantle. The Academy for Eating Disorders stated in its 2023 position paper that "calorie-focused tracking tools, when used without clinical supervision, carry measurable risk of relapse in individuals with restrictive eating histories" [4].

Coaching Is Not Therapy

Noom coaches are not licensed therapists, registered dietitians, or psychologists. They complete a Noom-internal certification program. A patient experiencing a binge-purge cycle, orthorexic spiraling, or acute body-image distress needs a licensed mental-health professional, not an app coach. Noom's own terms of service note that the platform "is not intended to diagnose, treat, cure, or prevent any disease or medical condition" [5].

The Numbers

The National Eating Disorders Association estimates that 28.8 million Americans will have an eating disorder at some point in their lifetime [6]. That is a substantial pool of individuals who may be drawn to a weight-loss app without disclosing their history.

Patient Profile 2: Patients Who Need Close Cardiometabolic Monitoring

A patient with type 2 diabetes on insulin or sulfonylureas, a recent cardiovascular event, stage 3+ chronic kidney disease, or uncontrolled hypertension above 160/100 mmHg needs more than an app.

GLP-1 Prescribing Without Lab Infrastructure

If a Noom Med prescriber writes semaglutide for a patient with type 2 diabetes who is already on metformin plus a sulfonylurea, the hypoglycemia risk requires active dose adjustment of the sulfonylurea, eGFR checks, and HbA1c monitoring. The SUSTAIN-6 trial (N=3,297) showed that semaglutide 0.5 mg and 1 mg reduced major adverse cardiovascular events by 26% vs. Placebo in high-risk T2D patients, but those patients were enrolled in a trial with intensive monitoring protocols [7]. Replicating the benefit outside that infrastructure requires the same monitoring discipline.

Blood Pressure and Heart Rate

GLP-1 receptor agonists produce a modest mean increase in resting heart rate of approximately 2-3 beats per minute, as documented in the SCALE Obesity and Prediabetes trial (N=2,254) [8]. For a patient with pre-existing tachycardia or a recent ablation procedure, that shift warrants clinical attention. An asynchronous telehealth prescriber reviewing a Noom Med intake form may not catch it.

CKD and Drug Clearance

Semaglutide is cleared renally. Patients with eGFR <30 mL/min/1.73m² require careful assessment before starting any GLP-1 agent, per FDA prescribing information for Wegovy [9]. Noom Med's intake process does not routinely include creatinine or eGFR data from a recent lab draw.

Patient Profile 3: Patients With Complex Psychiatric Histories

Noom markets its psychological approach as a strength. For patients with mild anxiety or subclinical low mood, app-based CBT micro-lessons are probably harmless. The picture changes for patients with bipolar disorder, active psychosis, severe major depressive disorder, or a history of suicidality.

Bupropion-Naltrexone Specifically

Noom Med can prescribe Contrave (bupropion 90 mg/naltrexone 8 mg). Bupropion carries an FDA black-box warning for increased suicidal thinking and behavior in patients under 24 and in those with a major depressive episode [10]. It is contraindicated in patients with a seizure disorder, current or prior bulimia, or current MAOI use. Asynchronous intake screening that relies on self-report alone may miss these contraindications.

The Coaching Gap

A Noom coach receiving a check-in message from a patient who reports feeling "hopeless" or "not worth it" is not trained to conduct a Columbia Suicide Severity Rating Scale assessment. The appropriate clinical escalation pathway in that scenario needs to be explicit, documented, and staffed. Noom's published materials do not describe a specific clinical escalation protocol beyond referring users to 988.

Patient Profile 4: Patients With BMI Below 25 Who Want GLP-1 Access

The FDA approved Wegovy (semaglutide 2.4 mg) for adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity [9]. Ozempic is approved for type 2 diabetes management, not weight loss per se.

The table below summarizes the FDA-approved GLP-1 weight-loss indications and the minimum BMI thresholds. Any platform prescribing below those thresholds is operating outside labeled indications.

| Drug | FDA Indication | Minimum BMI (no comorbidity) | Minimum BMI (with comorbidity) | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Chronic weight management | 30 | 27 | | Liraglutide 3 mg (Saxenda) | Chronic weight management | 30 | 27 | | Tirzepatide 2.5-15 mg (Zepbound) | Chronic weight management | 30 | 27 | | Bupropion/Naltrexone (Contrave) | Chronic weight management | 30 | 27 |

Patients with a BMI <27 who approach Noom Med hoping to access semaglutide for weight loss are either going to be declined (appropriate) or prescribed off-label (a red flag). Any telehealth platform willing to prescribe Wegovy to a patient with BMI <27 and no documented comorbidity is not following FDA-approved labeling [9].

Patient Profile 5: Patients Who Have Had Poor Outcomes With Subscription-Model Programs

This is less about clinical safety and more about financial harm and program fit. The volume of BBB complaints against Noom (B- rating, 1,400+ complaints) clusters heavily around billing practices [2]. A 2022 review of consumer complaints submitted to the FTC found that digital health subscription services generated more billing disputes per active user than almost any other consumer software category [3].

The Specific Pattern

Patients report: (a) purchasing a discounted annual plan, (b) attempting to cancel before auto-renewal, (c) finding the cancellation process requires a specific sequence of in-app steps that is not prominently disclosed, and (d) being charged for another year before the dispute is resolved. This pattern does not mean Noom is fraudulent, but it does mean a patient who has previously been harmed by subscription-trap billing should read the cancellation policy in full before entering a credit card number.

What to Verify Before Subscribing

Review the cancellation terms at the point of purchase, not after. Noom's terms require cancellation through the app settings rather than by emailing support or contacting a coach. Third-party payment platforms (Apple App Store, Google Play) have their own cancellation processes that differ from Noom's direct billing, and patients frequently confuse the two.

Patient Profile 6: Patients Seeking Compounded Semaglutide Through Noom

During the FDA shortage period for Wegovy and Ozempic (officially resolved for Wegovy in 2024 and for Ozempic 0.5 mg, 1 mg, and 2 mg pens in early 2025), many telehealth platforms offered compounded semaglutide [11]. The FDA has stated plainly that compounded semaglutide is not FDA-approved, and it has sent warning letters to multiple compounding pharmacies [11].

Current FDA Position

The FDA removed semaglutide from the official shortage list for the relevant Wegovy doses. Once a drug is off the shortage list, outsourcing facilities and state-licensed compounders lose the legal basis to produce copies of that drug under the shortage exemption in Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [11]. Any platform still advertising "compounded semaglutide" as of mid-2025 is prescribing a product that the FDA has explicitly flagged.

Patients who want semaglutide should receive FDA-approved Wegovy or Ozempic, filled at a licensed pharmacy, with a prescription from a clinician who has reviewed their history in a real-time encounter or a properly documented asynchronous encounter that meets their state's telehealth standard of care.

Is Noom Legit? A Structured Answer

"Legit" covers two different questions: Is Noom a real company with real products? Yes. Is Noom an appropriate medical-grade weight-loss solution for every patient who signs up? No.

Company Standing

Noom Inc. Is a registered Delaware corporation headquartered in New York. Its app is available on iOS and Android. Noom Med operates through licensed prescribers in states where telehealth prescribing is permitted. The company is not a scam in the sense of taking money without providing any service.

Clinical Legitimacy

The published evidence for app-based behavioral weight loss is real but limited. A 2016 study in Scientific Reports (N=35,921 Noom users) found a 77.9% of active users lost weight, with greater engagement predicting greater loss [12]. The study was observational, industry-adjacent, and did not use a randomized control arm, so it cannot establish causation. The effect sizes in independent RCTs of app-based CBT weight programs, like the 2021 Obesity Reviews meta-analysis cited above, are smaller than Noom's own marketing figures suggest [1].

LegitScript Verification

LegitScript, the pharmacy verification service referenced in NABP guidelines, does not list Noom Med as a verified telehealth pharmacy as of mid-2025. Patients who want to verify any telehealth prescriber's legitimacy should check LegitScript's database directly and confirm the prescribing clinician holds an active license in their state through the relevant state medical board.

When Noom May Be Appropriate

A complete clinical picture requires stating where the platform fits, not just where it fails.

Appropriate Use Cases

Noom's app-plus-coaching model may be reasonable for adults aged 18-65 with a BMI between 27 and 40, no active psychiatric illness, no current eating-disorder diagnosis, no major cardiometabolic comorbidities requiring active drug titration, and a preference for behavioral coaching over purely pharmacologic intervention. The 5-10% body weight loss range achievable with a structured behavioral program, as documented in NHLBI clinical guidelines on obesity treatment, is meaningful for reducing blood pressure, fasting glucose, and triglycerides [13].

Adults who want GLP-1 support and meet FDA-labeled BMI thresholds, have been cleared by a primary care physician, and have no contraindicated conditions may find Noom Med a convenient access point, provided they understand the asynchronous prescribing model and maintain a relationship with a primary care clinician for ongoing labs.